Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIpsen S.A.

Ipsen S.A.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
43.666 USD 0.00(0%)
Last update at 2026-11-05T21:00:00Z
VOLUME
50
Market Cap
15163.51M
P/E
25.65

Momentum Score

…

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
42.70
Low
43.67
High
52 Week Price Range
32.28
Low
50.28
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Ipsen S.A. is a France-based specialty biopharmaceutical company that researches, develops and commercializes treatments primarily in oncology and rare diseases, with a global commercial footprint. Long-term growth may be driven by its marketed specialty portfolio, a mid-to-late-stage clinical pipeline and geographic expansion of established products, which could support steady revenue streams and margin improvement.

The principal risks include reliance on a limited number of key products, clinical and regulatory setbacks, pricing and reimbursement pressure across markets, and exposure to currency and integration risk from strategic transactions.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
43.67
Dividend Yield
1.00%
Revenue TTM
4291.30M
Revenue Per Share
13.00
Gross Profit TTM
3476.20M
Debt / Equity
0.20
ROE
11.44%
Net Debt
-657.75M
ROCE
13.04%
Diluted EPS TTM
1.79

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 555.38M 432.20M 756.10M 706.10M 814.40M
Minority interest -1.00M -1.40M -2.80M 1.10M -0.10M
Net income 426.96M 345.90M 644.40M 648.60M 646.60M
Selling general administrative 219.00M 216.30M 217.80M 205.80M 199.60M
Selling and marketing expenses 944.40M 957.20M 917.10M 833.40M 835.70M
Gross profit 2492.20M 2955.80M 2735.20M 2628.80M 2461.10M
Reconciled depreciation 625.20M 705.90M 87.90M 336.50M 237.00M
Ebit 716.85M 455.40M 799.20M 729.90M 849.50M
Ebitda 1059.08M 1161.30M 887.10M 1202.30M 1109.30M
Depreciation and amortization 342.24M 705.90M 87.90M 472.40M 259.80M
Operating income 716.85M 496.70M 816.00M 729.90M 849.50M
Other operating expenses 2813.98M 3077.80M 2490.40M 2285.20M 2120.80M
Interest expense 34.68M 23.80M 37.70M 18.50M 23.70M
Tax provision 133.60M 74.90M 136.20M 112.30M 168.20M
Interest income - - - 0.50M 2.90M
Net interest income -75.80M -63.60M -54.50M -24.00M -37.30M
Income tax expense 128.33M 74.90M 136.20M 112.30M 168.20M
Total revenue 3530.82M 3574.50M 3306.40M 3156.50M 2999.10M
Total operating expenses 1775.35M 2459.10M 1919.20M 1757.50M 1582.80M
Cost of revenue 1038.62M 618.70M 571.20M 527.70M 538.00M
Total other income expense net -161.47M -64.50M -59.90M -23.80M -35.10M
Discontinued operations - - - 55.40M 55.40M
Net income from continuing ops 444.50M 357.30M 619.90M 592.10M 646.70M
Net income applicable to common shares - - - 648.60M 646.60M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6934.85M 6439.00M 6322.90M 5607.90M 5006.80M
Intangible assets 2287.23M 2518.40M 2678.80M 1585.40M 1391.90M
Other current assets 109.85M 359.30M 449.20M 239.50M -0.10M
Total liab 2599.89M 2257.20M 2499.10M 2271.20M 2252.80M
Total stockholder equity 4334.05M 4181.60M 3825.10M 3337.30M 2751.50M
Other current liab 544.75M 534.10M 777.60M 684.50M 339.80M
Common stock 83.76M 83.80M 83.80M 83.80M 83.80M
Capital stock 83.80M 83.80M 83.80M 83.80M 83.80M
Retained earnings 443.50M 345.90M 644.40M 648.60M 646.60M
Other liab - - - 268.80M 252.20M
Good will 633.53M 699.50M 663.90M 579.90M 623.10M
Other assets - - - 327.30M 257.10M
Cash 1524.85M 678.10M 528.40M 1169.30M 814.70M
Total current liabilities 1439.29M 1505.40M 1626.80M 1335.40M 1228.40M
Current deferred revenue 5.40M - 5.70M - 258.60M
Net debt -657.75M -251.30M -154.90M -501.70M -121.60M
Short term debt 35.30M 37.20M 36.40M 3.80M 35.30M
Short long term debt 4.00M 0.60M 9.00M 3.80M 5.50M
Short long term debt total 867.10M 426.80M 373.50M 667.60M 693.10M
Other stockholder equity -116.68M 3633.75M 10.90M 2604.90M 2021.10M
Property plant equipment - - - 581.40M 647.50M
Total current assets 2822.90M 2021.20M 1898.40M 2397.60M 1953.80M
Net tangible assets - - - 1172.00M 736.30M
Short term investments 1.00M 1.10M 10.60M 31.00M 42.40M
Net receivables 931.70M 697.20M 631.30M 673.70M 877.40M
Long term debt 748.20M 287.50M 269.70M 581.80M 562.80M
Inventory 256.49M 285.50M 289.50M 284.10M 219.40M
Accounts payable 853.84M 854.80M 771.40M 647.10M 594.70M
Accumulated other comprehensive income 4286.08M 4234.78M 3082.10M - -
Non currrent assets other 54.38M 76.80M 375.50M 37.20M 46.70M
Non current assets total 4111.95M 4417.80M 4424.50M 3210.30M 3053.00M
Capital lease obligations 114.90M 138.70M 27.40M 109.70M 124.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -676.60M -1072.20M -458.60M -28.40M
Change to liabilities - - - 29.10M 83.50M
Total cashflows from investing activities -590.92M -676.60M -1078.20M -458.60M -344.20M
Net borrowings 476.90M 44.20M -290.80M -34.50M -280.70M
Total cash from financing activities 286.62M -100.00M -435.80M -164.20M -401.20M
Change to operating activities - - - 38.50M -15.10M
Net income 426.00M 357.30M 617.10M 592.10M 646.70M
Change in cash 927.23M 158.10M -646.00M 356.40M 169.50M
Begin period cash flow 597.62M 519.50M 1165.50M 809.10M 639.60M
End period cash flow 1524.85M 677.60M 519.50M 1165.50M 809.10M
Total cash from operating activities 1093.47M 915.50M 865.90M 971.40M 909.20M
Issuance of capital stock - - 0.00M 0.00M 0.00M
Depreciation 625.20M 705.90M 87.90M 336.50M 237.00M
Other cashflows from investing activities 54.75M -438.40M -46.40M -76.10M 96.10M
Dividends paid 111.61M 99.60M 99.60M 99.30M 82.90M
Change to inventory 21.80M -20.00M -8.90M -19.90M -0.50M
Change to account receivables -127.08M -45.30M -1.60M -86.80M -67.30M
Sale purchase of stock -65.03M -36.50M -39.50M -11.30M -36.70M
Other cashflows from financing activities 5.19M -8.10M -5.90M 1209.70M -0.70M
Change to netincome - - - 139.70M 64.40M
Capital expenditures 101.14M 782.50M 182.90M 252.90M 427.70M
Change in working capital 0.29M -54.50M 76.10M -39.10M -32.20M
Stock based compensation 39.30M 29.50M 30.10M 26.50M 28.70M
Other non cash items 2.69M -122.70M 54.70M 55.40M -3.60M
Free cash flow 992.33M 133.00M 683.00M 718.50M 481.50M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IPSEY
Ipsen S.A.		 -
-%		 43.67 25.65 11.29 3.53 2.78 2.83 8.25
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Ipsen S.A.

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.

70 rue Balard, Paris, France, 75015

33 1 58 33 50 00

https://www.ipsen.com

5535

Name Title Year Born
Mr. David Loew MD, CEO & Director 1967
Mr. Aymeric Le Chatelier Exec. VP & Group CFO 1969
Dr. Aidan Murphy Ph.D. Exec. VP of Technical Operations 1966
Mr. Craig Marks Vice-Pres of Investor Relations NA
Mr. Francois Garnier Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer 1962
Ms. Gwenan White Exec. VP of Communications & Public Affairs NA
Mr. Regis Mulot Exec. VP & Chief HR Officer 1966
Mr. Stephan Gagne Head of New Tokyo Office NA
Ms. Dominique Bery Head of Nordics & Baltics 1971
Dr. Yan Moore M.D. Sr. VP & Head of Oncology Therapeutic Area 1967

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…